STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors
a study on Solid Tumor Lung Cancer Non-Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Skin Cancer/Melanoma Kidney Cancer Renal Cell Carcinoma Cervical Cancer Microsatellite Instability Stomach Cancer Esophageal Cancer Transitional Cell Carcinoma Mismatch Repair Deficiency Carcinoma Head and Neck Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedcompletion around
Description
Summary
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
Official Title
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 As a Single Agent and in Combination Therapy in Patients with Selected Advanced Solid Tumors
Details
The phase 1a portion of the study is a dose escalation design to evaluate STK-012 as monotherapy and in combination therapy in patients with selected solid tumors. The phase 1b portion of the study includes dose expansions to evaluate STK-012 as monotherapy and in combination therapy at the candidate recommended phase 2 dose (RP2D) in selected solid tumor types.
Keywords
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency, Carcinoma, Melanoma, Squamous Cell Carcinoma of Head and Neck, Microsatellite Instability, Carboplatin, Pembrolizumab, Pemetrexed, STK-012
Eligibility
For people ages 18 years and up
Selected Inclusion Criteria:
- Participants enrolled to STK-012 monotherapy dose escalation and expansion and STK-012 + pembrolizumab combination dose escalation must have selected tumor types and progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment.
- Participants enrolled to STK-012 + pembrolizumab combination dose expansion must have selected tumor types and may not have received treatment for metastatic disease.
- Participants enrolled to STK-012 dose escalation combination treatment with pembrolizumab, pemetrexed and carboplatin must have NSCLC and may not have received treatment for metastatic disease.
- Participants enrolled to STK-012 dose expansion combination treatment with pembrolizumab, pemetrexed and carboplatin must have PD-L1 negative NSCLC and may not have received treatment for metastatic disease.
Selected Exclusion Criteria:
- Received systemic anti-cancer therapy within 3 weeks of the first dose of study treatment or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.
- Received radiotherapy within 2 weeks of the first dose of study treatment.
- Received prior IL-2-based or IL-15-based cytokine therapy.
- Participants with NSCLC may not have any known actionable genetic aberrations with approved therapies.
Locations
- UC San Diego Moores Cancer Center
accepting new patients
La Jolla California 92093-0698 United States - UCLA Hematology/Oncology - Santa Monica
accepting new patients
Santa Monica California 90404 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Synthekine
- ID
- NCT05098132
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 202 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.